The following two biomedical companies – Gyroscope Therapeutics in Stevenage UK and Orbit Biomedical in Philadelphia, US – have announced that they have merged in… Read More »Gyroscope Therapeutics and Orbit Biomedical have merged into a new retinal gene therapy company
Global news reports have highlighted a lawsuit in 44 states in the US for price-fixing and collusion among several large pharmaceutical companies. Following for the… Read More »Drug companies sued in multiple States over price-fixing of generic drugs, several leading up to 1,000% increase of cost to patients
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), have announced a collaboration to “discover, develop and commercialize new RNA interference (RNAi) therapeutics for… Read More »Alnylam Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc. have established a new RNAi collaboration for the development of ocular and CNS treatments
Nightstar Therapeutics plc,. (NASDAQ: NITE), has reported that an acquisition agreement with Biogen is to be completed in mid-year 2019 for an estimated $877M. Nightstar… Read More »Nightstar Therapeutics plc (Waltham, Mass. and London) is acquired by Biogen (Switzerland) for an estimated $877M
Spark Therapeutics Inc,. has reported that a definitive merger agreement with Roche to acquire Spark at a price of $114.50 per share in an all-cash… Read More »Spark Therapeutics (NASDAQ: ONCE) confirms that a definitive agreement will merge with Roche
Research published by several investigators in UK universities, including York University, King’s College, London and Queen Mary University, London, states that “the uncertainty of a… Read More »A “no deal” Brexit scenario may start a domino effect for a “collapse” in the UK pharmaceutical industry
Annexon Biosciences Inc. (San Francisco, California, USA) has raised $75 million investment to fund development of its lead complement inhibitors through several clinical stages, according… Read More »Annexon Biosciences Inc. has raised over $75M investment to build classical complement pathway treatments
Applied Genetic Technologies Corporation (NASDAQ: AGTC), a gene therapy company, indicated that a treatment of a X-linked retinoschisis (XLRS) disorder has confirmed that interim six-month… Read More »Applied Genetic Technologies Corporation (ACGT Inc.) have terminated a gene therapy study for X-linked retinoschisis
Bayer and Novartis may appeal to a UK ruling on how Avastin (bevacizumab) will be allowed for doctors use lawful medication. The main crux of… Read More »Bayer and Novartis may appeal ruling in the UK on lawful use of Avastin (bevacizumab) for wet AMD
A commercial gene therapy company, Spark Therapeutics (NASDAQ:ONCE), announced that Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMA), has granted marketing authorization… Read More »The European Commission (EC) approves “Luxturna” (voretigene neparvovec), a recently developed gene therapy product to treat Leber congenital amaurosis (RPE65 mutations)